FirstView Insight "Uveitis" provides in depth understanding of historical and forecasted epidemiology along with the detailed market insights. The report covers detailed information on the disease, treatment algorithm, existing treatment and upcoming treatment regimens, unmet needs, market drivers, market barriers, sales trend and market revenue during study period 2018-2029.
Geography Covered
- United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
Duration of study: 2018-2029
Report coverage:
Uveitis Overview
This report contains comprehensive overview of disease including disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends, as well as details about treatment algorithms and treatment guidelines for Uveitis
Uveitis Epidemiology & Forecast
This section encompasses information on the incidence and prevalence of disease in EU5, US & Japan. It also provides historical, current and forecasted estimates of diagnosed/treatable patient population.
Uveitis existing and upcoming treatment landscape
Captures the evolution of treatment paradigm including the current and emerging drug therapies. Provides information on the clinical trial results, mechanism of action, route of administration, therapeutic positioning, regulatory milestones and patent exclusivity. It gives insight into the potential therapeutic targets for drug development. The section also covers major events and latest happenings, deals and collaborations.
Uveitis Market Size
This section of report will address the major issues, on the size and total addressable market share for Uveitis. This will help the companies to understand and visualize their business prospects and make major decisions based on the historical, current and forecasted market share across the globe. Analyse the commercial potential of the product as well as the disease/therapy area.
Uveitis Market Trends & Unmet needs
This section of the report helps to understand the market trend and opportunities by analysing the impact of current therapies on the market, current and future unmet needs, drivers and barriers and demand of better technology. This is determined by analysing the impact of various factors such as mechanism of action, route, cost of therapy, patient segmentation, existing available treatments, compliance and need of the market, expected launch timelines, competitors, brand value and KOLs perception.
Methodologies
Our research team is guided by senior market research expert with specialized experience and diversified exposure, we collect data, analyze, and disseminate periodically to all our stakeholders. We collect information through primary research and secondary databases such as company website, SEC filings, clinical trial databases, news media, press releases, journal articles, regulatory bodies, HTA website, etc. to provide complete picture of the market. We insure our report provides a complete and dynamic valuation of pharma assets, which will provide insight for decision making, and transform business processes to provide.
Major highlights of the report
- Detailed analysis of existing and upcoming competitive landscape
- Estimation of Market Size in 7MM
- CAGR of the market during the forecast period 2018-2029
- Factors to determine the market growth for Uveitis
- Determine drug uptake, key competitors
- Impact of emerging/upcoming therapies on Uveitis
- Determine the unmet need, major barriers and drivers across the industry
- Disease overview:
- Pathophysiology
- Symptoms
- Etiology
- Diagnosis
- Etiology
- Treatment Algorithm
- Treatment Options
- Overview of Marketed drugs
- Drug 1
- Drug Description
- Mechanism of Action
- Regulatory Milestones
- Clinical Trial Details and Results
- Adverse Events
- Sales data
- Patent Exclusivity
- Drug 1
- Overview of Major Pipeline Drugs
- Drug 1
- Drug Description
- Clinical Trial Details and Results
- Product Development Activity
- Regulatory Milestones
- Expected Launch Date
- Drug 1
- Patent Information
- Patent Expiry in United States (US)
- Patent Expiry in European Union (EU)
- Patent Expiry in Japan
- Historical and Forecasted sales of marketed drugs
- Global Epidemiology of Uveitis Forecasted to 2029
- Current Epidemiology of Uveitis & Forecasted to 2029 by 7 Major Markets (7MM)
- Epidemiology of United States-2029
- Epidemiology of United Kingdom-2029
- Epidemiology of Germany-2029
- Epidemiology of France-2029
- Epidemiology of Spain-2029
- Epidemiology of Italy-2029
- Epidemiology of Japan-2029
- Epidemiology of Emerging Markets-2029
- Global Market size (2018-2029)
- Global Forecasted Market size (2018-2029)
- Global Market Size by Geography
- Market size of US (2014-2018)
- Forecasted Market size of US (2018-2029)
- Market size of Europe
- Market size of Germany (2014-2018)
- Forecasted Market size of Germany (2018-2029)
- Market size of United Kingdom (2014-2018)
- Forecasted Market size of United Kingdom (2018-2029)
- Market size of France (2014-2018)
- Forecasted Market size of France (2018-2029)
- Market size of Italy (2014-2018)
- Forecasted Market size of Italy (2018-2029)
- Market size of Spain (2014-2018)
- Forecasted Market size of Spain (2018-2029)
- Market size of Japan (2014-2018)
- Forecasted Market Size of Japan (2018-2029)
- Market size of Emerging Markets (2014-2018)
- Forecasted Market size of Emerging Markets (2018-2029)
- Market Trends
- Market Opportunity Assessment
- Drivers and Barriers
- Unmet Needs
- SWOT Analysis
- Appendix
- Report Methodology
- Consulting Services
- Disclaimer
List of Tables
Table 1: Global Market Size of Uveitis in USD Million (2018-2029)
Table 2: 7 MM Market Size of Uveitis in USD Million (2018-2029)
Table 3: Diagnosed Cases Uveitis in United States (2018-2029)
Table 4: Diagnosed Cases Uveitis in Germany (2018-2029)
Table 5: Diagnosed Cases Uveitis in France (2018-2029)
Table 6: Diagnosed Cases Uveitis in United Kingdom (2018-2029)
Table 7: Diagnosed Cases Uveitis in Spain (2018-2029)
Table 8: Diagnosed Cases Uveitis in Italy (2018-2029)
Table 9: Diagnosed Cases Uveitis in Japan (2018-2029)
Table 10: Diagnosed Cases Uveitis in Emerging Market (2018-2029)
Table 11: List of Marketed Drugs for Uveitis
Table 12: List of Pipeline Drugs for Uveitis
Table 13: United States Market Size of Uveitis in USD, Million (2018-2029)
Table 14: Germany Market Size of Uveitis in USD, Million (2018-2029)
Table 15: France Market Size of Uveitis in USD, Million (2018-2029)
Table 16: United Kingdom Market Size of Uveitis in USD, Million (2018-2029)
Table 17: Spain Market Size of Uveitis in USD, Million (2018-2029)
Table 18: Italy Market Size of Uveitis in USD, Million (2018-2029)
Table 19: Japan Market Size of Uveitis in USD, Million (2018-2029)
Table 20: Emerging markets Market Size of Uveitis in USD, Million (2018-2029)
List of Figures
Figure 1:Types of Uveitis
Figure 2:Stages of Uveitis
Figure 3: Pathogenesis of Uveitis
Figure 4: Risk Factors of Uveitis
Figure 5:Treatment for Uveitis
Figure 6: Diagnosed Cases of Uveitis in United States (2018-2029)
Figure 7: Diagnosed Cases of Uveitis in Germany (2018-2029)
Figure 8: Diagnosed Cases of Uveitis in France (2018-2029)
Figure 9: Diagnosed Cases of Uveitis in United Kingdom (2018-2029)
Figure 10: Diagnosed Cases of Uveitis in Spain (2018-2029)
Figure 11: Diagnosed Cases of Uveitis in Italy (2018-2029)
Figure 12: Diagnosed Cases of Uveitis in Japan (2018-2029)
Figure 13: Diagnosed Cases Uveitis in Emerging Market (2018-2029)
Figure 14: Total 7 Major Market Size of Uveitis in USD, Million (2018)
Figure 15: Total 7 Major Market Size of Uveitis in USD, Million (2029)
Figure 16: United States Market Size of Uveitis in USD, Million (2018-2029)
Figure 17: Germany Market Size of Uveitis in USD, Million (2018-2029)
Figure 18: France Market Size of Uveitis in USD, Million (2018-2029)
Figure 19: United Kingdom Market Size of Uveitis in USD, Million (2018-2029)
Figure 20: Spain Market Size of Uveitis in USD, Million (2018-2029)
Figure 21: Italy Market Size of Uveitis in USD, Million (2018-2029)
Figure 22: Japan Market Size of Uveitis in USD, Million (2018-2029)
Figure 23: Emerging markets Market Size of Uveitis in USD, Million (2018-2029)